

Review- Using the Traditional Herbs for Treatment of Coronavirus

Semaa Hassen Shalal¹, Rawaa Bannay Zubairi², Bassam A. Hassan³.

1& 3 Lecturer at Department of Pharmaceutical Chemistry, College of Pharmacy, Thi-Qar University, Iraq.

2 Basrah technical institute, Southern Technical University, Iraq.

Co-authors Email : bassamalsafee@utq.edu.iq ,rawa@stu.edu.iq

Abstract

In the presence of study we using the Traditional Herbs for Treatment of Coronavirus. Coronaviruses are members of the Coronaviridae family as clarified in the beginning of the sixties of the last century. SARS-CoV-2 has a genomic architecture that is comparable to that of other betacoronaviruses, with a 50-kb genome. (untranslated region), a Nonstructural proteins are encoded by the replicas complex (orf3ab). Available therapy for treatment COVID19. Therapeutic monoclonal antibodies (mAbs) have been used to treat a vary try of human ailments and have emerged as a popular class of pharmaceuticals in recent years.

Herbal Medicine Candidates the therapeutic usefulness of plants is being called into question. Antiviral, anti-inflammatory, immunomodulatory, and mixed effects drugs with more than one purpose are often classed as antiviral, anti-inflammatory, immunomodulatory, and mix effects drugs with valuable efficacy.

Keywords: Coronavirus, Herbs, Traditional, Treatment.

1.INTRODUCTION :

Coronaviruses are members of the Coronaviridae family as clarified in the beginning of the sixties of the last century. Corona is a Latin word that means "Crown" or "Halo," and it is a one-of-a-kind word. two-dimensional transmission electron microscopy appearance and it appears that peplomers with club-shaped spikes are covering their feet surfaces. The coronaviruses and belong to the Coronaviridae subfamily are able to be passed from one person to another. Coronavirus strains are created "from the ground up". "Rousettus leschenaultii" is a bat species. Coronaviruses come in a variety of strains. MERS-CoV, SARS-CoV, and SARS-CoV-2 are three types of coronavirus [1].

Coronaviruses are positive-sense RNA viruses with enormous viral RNA genomes that are single-stranded. SARS-CoV-2 has a genomic architecture that is comparable to that of other beta-coronaviruses, according to recent research. A replicase complex consists of a 50- untranslated region (UTR orf1ab) is a gene that codes for non- structural proteins [2]

COVID-19 is caused by SARS-CoV-2, which was identified "in Wuhan, China in December 2019 .

(WHO) The World Health Organization classified COVID-19 a pandemic on Marche 11 , 2020 , because to its widespread dissemination and infection rates. [3]

More than 159 million worldwide confirmed cases and more than 3 million fatalities had been reported as of May 11, 2021. The first verified case was announced in Peru on March 8, 2020, and the number of cases quickly grew despite the Peruvian government's efforts. Peru has surpassed Brazil as the Latin American country with the greatest number of COVID-19 infections and deaths in less than four months. People's lifestyles changed as a result of their physical seclusion.

The majority of COVID-19 patients first experienced fever, cough, and weariness before developing additional symptoms such as muscular soreness, headache , shortness of breath , and diarrhea , which, in extreme circumstances, can result in lethal inflammatory reactions. [4]

Coronaviruses have Several types infect different organisms as mouse hepatitis virus which infect mice, porcine epidemic diarrheaa virus (PEDV) which infect pigs ,avian coronavirs which infect birds and human coronavirus(HCoV) which infect human like HCoV-OC43, SARS-

CoV, SARS-CoV-2, HCoV-NL63, Middle East Respiratory Syndrome-CoV (MERS-CoV), HCoV-229E are cause severe acute respiratory syndrome.


COVID-19 causes an immunological response that is inflammatory. In cases with COVID-19, the release of iinflammatorycytokines causes cytokine storm and immunity to be disrupted, as well as acute respiratory distress syndrome and multiorgandysfunction . Several types of vaccines are already availabilityfor prevented the COVID-19 pandemic , but delivery remains a barrier, particularly in impoverished nations. Remdesivir is an antiviral medication that was recently authorized but is in short supply [5] .

The population's idiosyncrasies have also concentrated on the use of antiviral and anti-inflammatory medicinal herbs, natural products, or preparations to enhance the immune system or cure respiratory ailments. Medical plants and bioactive chemicals previously have showedantiviral activity against SARS-CoV-1 and MERS-CoV showed to have efficacy of potential against SARS-CoV-2. . This potential activity is thought to be caused via action on the

ACE-2 receptor, 3CLpro, and other SARS-CoV-2 viral protein targets. Another approach has been to utilize computational tools to uncover potential inhibitory medicines for the active binding sites of the SARS-CoV-2 target proteins. MSCs and MSCs-Exo (MSC exosomes) have also found to minimize the risk of lung damage induced by alveolar inflammation and related clinical scenarios, like the one reported in COVID-19 patients. *Malvasylvestris* L. (Malvaceae) contains Polysaccharides, *Aloe barbadensis* Mill (Asphodelaceae) has HF1Z (polysaccharide), *Salvia officinalis* L. (Lamiaceae) has Polysaccharide, *Cynarascolymus* L. (Compositae) has Cynaroside, *Erigeron abajoenis* Cronqui (Scutellari)..

2. Characteristic of SARS-CoV-2

SARS-CoV-2 has a genomic architecture that is comparable to that of other betacoronaviruses, with a 50-kb genome (Figure 1). -UTR (untranslated region), a Nonstructural proteins are encoded by the replicase complex (orf1ab).[6]



[Figure 1]

Despite being categorized as a beta-coronavirus, SARS-CoV-2 is distinct from MERS-CoV and SARS-CoV. According to recent research, the SARS-CoV-2 genes share 80% of their nucleotide sequences. SARS-CoV genes have 89.10 percent nucleotide identity then 89.10 percent nucleotide similarity. Beta-coronaviruses typically create an 800 kDa polypeptide. as the genome is being transcribed This polypeptide is proteolytically active. cleaved to produce a variety of proteins. Proteases are enzymes that break down proteins. The papain-like protease (PLpro) and 3-reductase enzymes are involved in cessation. chymotrypsin-like protease is a kind of chymotrypsin (3CLpro). The polymer is cleaved by the 3CLpro protein at 11 different places to produce a variety of non-structural proteins. Important proteins for viral replication. 3CLpro is involved in the replication of virus particle and, unlike structural/accessory protein encoding genes, it is found at

the 30 end of the genome, where there is a lot of variation. Finally the a result, it might be a excellent candidate for anti-coronavirus inhibitors. Potential inhibitors for SARS-CoV and MERS-CoV 3CLpro been identified by structure-based activity assessments and high-throughput experiments. Medicinal plants, particularly those used in traditional Chinese medicine, have sparked interest due to they contain bioactive chemicals that might be exploited to make formal medications with no or low adverse effects against a variety of disorders. As a result, the current investigation was carried out in order to acquire structural insight into the SARS-CoV-2 3CLpro and to identify powerful anti-COVID-19 natural chemicals. [6] [Table 1] SARS-structure. CoV-2's SARS-CoV-2, known on other hand as the severe respiratory acute syndrome coronavirus 2, is one of the coronaviruses [7].

Coronavirus is a type of coronavirus that is found in the environment. Complementary and Alternative Medicine with Evidence RBD interacts with the ACE2 receptor in the S1 region of the viral S protein. following that is contacted, the viruses requires entrance to the cytoplasm of the host cell, which is provided via acid dependent proteolytic cleavage of the spike protein by a cathepsin or else protease. The internalisation processing then begins with the fusion of the coronaviruses with the host cell membrane. Within the S2 region, the spike protein is cleaved at twice locations. Eventual initial cleavage is required to separate the S proteins RBD and fusion domains. The alternative option is to expose or break the fusion peptide at S2[8].

within acidified endosomes is where the viruses and the host cell fused (this occurring in most cases) have the ability of fusion peptide (is enters to the membrane at S2) because it can merge at the plasma membrane (like in others some coronaviruses), this process is exposed by the cleavage.

In the next step, the antiparallel six-helix bundle formed by two heptad repeats in S2 is united.

the viral and host cell membranes are combined because of Bundle creation. In these conditions, the viral genome enters the cytoplasm. like any infection, the immune system will be activated after it. The COVID-19 pathogenesis is in the primary investigation, so there is missing serological evidence on SARS-CoV-2 and the initial site of SARS-CoV-2 infection is unknown.

it usually mainly affects the lungs in most patients so COVID-19 is a respiratory disease.

particular comorbidities with clinical symptoms of this infection cause deterioration in some patients. method of infection is close contact (Human to human transfer), the possibility of transmission by droplets is increased by close contact. May be from COVID-19 patients interacting or coughing, or from health staff and sneezing. in the incubation period, during lasts between 2 and

14 days, the virus can be transported. What is the disease's rate of spread? the disease's rate of spread ranges from 2.2 to 2.6, which means 2.2 and 2.6 persons are probably infected because of one sick person raised level of the disease's rate of spread is caused by the manner of infection [9]. immunoglobulin M (IgM) in most patients is increased 9 days after the start of COVID19, after that in the second week changed to immunoglobulin G (IgG). viral load rises fall in the second, when it in the first week of the sickness, this how some researches show. about day ten the +en, IgM and IgG levels will start to rise.[10]

Table 1

Physicochemical parameters of SARS-CoV-2 3CL^{pro}.

Parameters	SARS-CoV-2 3CL ^{pro}
Mol. Weight	33796.64 Dalton
No. of amino acids	306
Theoretical pI	5.95
Instability index (II)	27.65 (stable)
No. of negatively charged residues (Asp + Glu)	26
No. of positively charged residues (Arg + Lys)	22
Aliphatic index	82.12
Grand average of hydropathicity (GRAVY)	-0.019
Atomic composition	Carbon-1499; Hydrogen-2318; Nitrogen-402; Oxygen-445; Sulfur-22
Amino acid composition	Ala-17 (5.6%); Arg-11 (3.6%); Asn-21 (6.9%); Asp-17 (5.6%); Cys-12 (3.9%); Gln-14 (4.6%); Glu-9 (2.9%); Gly-26 (8.5%); His-7 (2.3%); Ile-11 (3.6%); Leu-29 (9.5%); Lys-11 (3.6%); Met-10 (3.3%); Phe-17 (5.6%); Pro-13 (4.2%); Ser-16 (5.2%); Thr-24 (7.8%); Trp-3 (1.0%); Tyr-11 (3.6%); Val-27 (8.8%); Pyl-0 (0.0%); Sec-0 (0.0%)

3.Available therapy for treatment COVID19

Therapeutic monoclonal antibodies (mAbs) have been used to treat a variety of human ailments and have emerged as a popular class of pharmaceuticals in recent years .


Many therapeutic mAbs have licensed by the Food and Drug Administration (FDA) and are currently being utilized in clinical trials for the treatment of human diseases such as malignancies, autoimmune diseases, met abolic diseases, and infectious diseases.

The use of mAb overcomes the limitations associated with other passive immunization approaches, particularly serum immunotherapy or intravenous immunoglobulin , in terms of specificity , safety because of low danger of human pathogen contamination, functionality, and

purity. Palivizumab was the first monoclonal antibody to be approved by the FDA for the treatment of respiratory syncytial virus-related lung illness in 1998. Since the first approval of mAb in 1998, other mAbs for infectious disease therapy have been developed. Recently, therapeutic mAbs that have the potential to treat coronavirus infection were found. CoV-specific mAbs targeting S or RBD have been shown to have antiviral activity. Interfering with RBD's cellular receptor binding reduces viral load. [11]. Furthermore, S-specific mAbs impede viral-cellular membrane fusion in the post-fusion stage, prevent viral entry and infection. As a result, producing neutralizing antibodies specific for CoV S or RBD could be a useful passive immune prophylaxis method. Several mAbs with therapeutic potential have been described for SARS-CoV, MERS-CoV [12], and even SARS-CoV-2. Vaccination, on the other hand, is the effective method for preventing infectious diseases in terms of developing very long term specific immunity [13], reducing severity, and lowering mortality. S protein is a significant antigenic determinant that contains neutralizing epitopes, and so it is a major aim for vaccine development. S specific antibody isolated from recovered SARS and MERS patients, in particular, demonstrated long-lasting and immunodominant antiviral activity. Furthermore, research in pre-clinical animal models revealed that the strong humoral and cellular immunological responses were elicited by the S protein. As a result, the S protein is regarded to be a promising vaccination candidate. Various vaccination platforms, including live-attenuated, inactivated, viral RNA, viral DNA, viral vector, and recombinant protein-based vaccines, have been employed in the development of SARS-CoV and MERS-CoV vaccines, which are either in pre-clinical research or clinical trials. Animal research has been conducted on adenovirus vector, DNA, and protein subunit vaccines targeting the MERS-CoV S protein, notably the RBD domain. GLS-5300, a DNA-based vaccination based on tDNA, increased MERS-CoV protection. By inducing powerful neutralizing antibodies, it was used to conduct clinical studies in macaques. The GLS300 vaccination successfully generated immunological responses in up to 85% of individuals while causing no serious adverse effects. After two shots, the effects are [14].

Immunogenicity of recombinant MERSCoVRBD-based subunit vaccines in animal models is increased by evoking powerful neutralizing antibodies and cellular immunity against MERS-CoV, cross-neutralizing human and camel MERS-CoV strains, and giving long-lasting protection for 6 months. CoronaVac (also known as PiCoVacc) is a whole-inactivated SARS-CoV-2 vaccine developed by Sinovac Biotech in Beijing; BBV152 (Bharat Biotech) is an inactivated SARS-CoV-2 vaccine; mRNA-1273 (Massachusetts-based biotechnology company Moderna) is an inactivated SARS-CoV-2 vaccine; BNT162b2 (BioNTech/Pfizer) is an inactivated [15].

A bridge to vaccines: Monoclonal antibodies could save lives and slow the spread of the coronavirus




4. Herbal Medicin Candidates

Single plant species have a great deal of therapeutic potential in the field of herbal medicine. Now that it's well acknowledged that a single plant has a diverse spectrum of biochemicals, the medicinal usage of plants is being called into question. Antiviral, anti-inflammatory, immunomodulatory, and mixed effects therapies with considerable success evidence are usually classed as antiviral, anti-inflammatory, immunomodulatory, and mixed-effects treatments. Inflammatory markers like interleukin (IL)-6, erythrocyte sediment rate (ESR), and C-reactive protein (CRP) have been linked to severe illness and poor outcomes, most likely due to cytokine storms, and herbal medicines with anti-inflammatory properties may play an important role in COVID-19 treatment.

4.1. *Eurycoma longifolia*

Today's market has standards and safety data in place. The standardized aqueous extraction of *Echinacea longifolia* has no direct antiviral characteristics that have been published with clinical data, but at a safe dose of 200 mg per day, it has good benefits in producing immunity in the elderly by increase the numbering of CD4+ cells. [16]. In animals, the same extract was somewhat mutagenic but showed no genotoxic effects [17]. Anti-inflammatory activities of *E. longifolia* have also been demonstrated in preclinical studies. Three anti-inflammatory bioactive compounds isolated from *E. longifolia* exhibit significant NF- κ B inhibitory effects: eurycomalactone, 1-4-1-5-dihydroklausone, and 1-3-2-1 dehydroeurycomanone [18]. In RAW macrophages activated with lipopolysaccharide, several phenolic components isolated from the roots of *E. longifolia* have been demonstrated to suppress the production of IL-6. Animal experiments done according to the Organization for Economic Co-operation and Development (OECD) regulations reveal that the standardized aqueous extract of *E. longifolia* has no detrimental effects (acute, subacute, and 90 days subchronic general toxicity studies). [19]. *E. longifolia*'s safety profile has been well-documented, although more study into *E. coli*'s anti-inflammatory effects is required. *longifolia* is a plant that grows in the environment of COVID-19 therapeutic and preventative mechanisms [20]. To summarize, the medicinal herbs *Gymnanthemum mygdalina*, *Azadirachta indica*, *Nigella sativa*, and *Eurycoma longifolia* may have a role in the prevention and treatment of COVID-19.




4.2. *Mentha piperita*

The world's oldest herbal remedy for a number of diseases is peppermint (*M. Piperita*). Dry peppermint used in traditional Chinese medicine since 1000 BCE, and its usage in ancient Egypt, Greece, and Egypt has been documented. Peppermint essential oil has significance antimicrobial and antifungal action against Gram-negative and Gram-positive bacteria, yeast, and fungus due to the phytochemistry menthol and menthone. [21]. However, a Saudi Arabian study found that, as a

result of the COVID pandemic, 78 percent of non-hospitalized patients used peppermint, compared to only 22 percent of hospitalized patients who did not, and that peppermint use during infection with COVID-19 was linked to reduced risk of death.



4.3. *Allium sativum* and *Allium cepa*



Garlic (*Allium sativum*) and onion (*Allium cepa*) are widely used in Ethiopia as home treatments for a wide range of diseases. Onion, which has long been used in traditional medicine to treat a range of ailments and infections, was used to kill the avian influenza virus (H9N2). On the other hand, the method of preparation is crucial, as boiling or frying onions is ineffective. According to studies, onions are a good alternative for treating COVID-19 patients because of their anti-inflammatory, antithrombotic, and antiviral capabilities. The most often used qualities include immunomodulatory, antioxidant, anti-inflammatory, antihypertensive, antithrombotic, antidiabetic, anticarcinogenic, antimutagenic, antibacterial, and prebiotic. Active metabolites

discovered in garlic include sulfur-containing and containnon-sulfur- molecules. Allicin and alliin, both sulfur-containing chemicals are the most prevalent.

4.4.Malvasylvestris



Malvasylvestris is used to treat a variety of respiratory ailments, including dry cough and pharyngeal and oral irritations [23]. According to preclinical research, flavonoids (e.g., delphinidin, apigenin, malvidinn, myricetin, genisteinn, and derivatives), mucilage (mainly galacturonic acids and glucuronic acid), tannins (hydroxycinnamic acid and derivatives), aromatic benzoic acid derivatives, and monoterpenes) are among the chemical constituents Malvaasylvestriss formulations have been explored for cough Isolated rhamnogalacturonan and mucilage were tested in cats for its antitussive effects. Both medicines suppressed coughing and decreased cough frequency, particularly in the laryngopharyngeal region. Another study [25] found analgesic and anti-inflammatory effectiveness in in-vivo animals. Malvasylvestris has traditionally been used to cure coughs.

4.5.Isatisindigotica

Organic acids, lignanss, alkaloids, nucleosidess, flavonoids, steroidss, and amino acids make up Isatisindigotica (I. indigotica). Antibacterially, anti-inflammatory, immunoregulatory, cholagogic, and antiviral properties have been discovered in I. indigotica in previous investigations. It can suppress a wide range of viruses, including hepatitis B, influenza, herpes simplex, mumps, coxsackievirus, and others. In clinical practice, it is widely used to treat viral illnesses such as parotitis, viral hepatitis, and viral influenza. As a result, I. indigotica might be useful in treating COVI-19. Immune modulation is a function of I. indigotica, and it helps it to fight viruses.

As a consequence, indigotica might be beneficial in the treatment of COVID-19, while further study is needed [26]



4.6.Psoraleacorylifolia:

In Chinese medicine and traditional Ayurveda, *Psoralea corylifolia* L is used to cure a range of skin disorders, including leukoderma, psoriasis, and leprosy. The antibacterial and anti-inflammatory effects of this plant are well-known. Six aromatic components isolated from *Psoralea corylifolia* seeds were discovered to inhibit the enzyme dose-dependently, with IC₅₀ values ranging from 4.2 to 38.4 M. At nanomolar concentrations, some natural substances (e.g., homoharringtonine, ouabain, lycorine, tylophorine, 7-methoxycryptopleurine, and Silvestro) have exhibited antiviral activity against SARS-CoV. Clinical trials of a fewestherbacesmedicineagainstt SARS-CoV-2-3CLPro sparked expectations for plant-based anti-SARS-CoV-2 therapies. The 3CL protease inhibitor NLC-001, a plant product used orally as a dietary supplemental, has been authorized by the US Food and Drug Administration.



4.7.Glycyrrhizaglabra :

Glycyrrhizin, also known as glycyrrhizic acid (GLR), is a saponin obtained mostly from the roots of the plant *Glycyrrhizae Radix*. GLR was found to be effective in suppressing twice clinical isolates

of SARS-associated coronaviruses (FFM-1 and FFM-2). The medicine was shown to have an EC₅₀ of 300 mg/ml for decreasing the virus's cytopathic impact while remaining non-cytotoxic to the host cells. GLR inhibited viral growth, penetration, and adsorption into cells. Although a drug-induced production of nitrous oxide synthase was documented, suggesting that nitrous oxide may be to blame for viral replication inhibition, the mechanism of activity at the source of this activity remained unclear at the time.

5. Conclusion and Recommendation

On the basis of the above discussion, we assume these herbal remedies may have the potential to limit the synthesis and release of proinflammatory viral proliferation in host cells, as well as alter some RAA-related biochemical pathways. Herbal agents may be effective in the battle of COVID-19. Finally, patients should be advised that using a supplement contain one of these medicines to prevent or repair COVID-19 without obtaining specific counsel or under the supervision of a professional is still not recommended if the patient is in excellent health. When providing these herbal remedies, the practitioner should proceed with caution. Even if the patient is in good health, the practitioner should take caution when providing these herbal remedies because there is a lot of conflicting information out there. There's a potential that these medications will help us. It's probable that it has anything to do with the induction of negative consequences. Additionally, these have been tested in both preclinical and clinical trials. Herbal COVID-19 agents have not been well developed. As a result, more investigations are being launched into this. Herbal medicine has the potential to be a platform for dealing with COVID-19 viral management in a variety of ways. Herbal therapy and its bioactive components may be effective in the prevention and treatment of COVID-19, according to the World Health Organization (WHO), which has licensed Remdesivir as an antiviral drug for use in emergency situations. Different plant biochemical components are the most desired. Herbal drinking or fruit may be administered as adjuvant components in COVID-19 care, as well as to lower fever and cough, the most frequent COVID-19 complication, through their anti-inflammatory actions. *Gymnanthemum*, *Amygdalinum*, *Azadirachta indica*, *Nigella sativa*, and *Eurycoma longifolia* are some herbal preparations. [30-48].

6. Reference:

- 1- Sabarianandh, J. V., Bernaitis, L., & Manimekalai, K. (2020). COVID-19 in Siddha Medicine: A Review. *J Basic Clin Appl Health Sci*, 3(2), 83-86.

- 2- ulQamar, M. T., Alqahtani, S. M., Alamri, M. A., & Chen, L. L. (2020). Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. *Journal of pharmaceutical analysis*, 10(4), 313-319.
- 3- Villena-Tejada, M., Vera-Ferchau, I., Cardona-Rivero, A., Zamalloa-Cornejo, R., Quispe-Florez, M., Frisancho-Triveño, Z., ... &Yañez, J. A. (2021). Use of medicinal plants for COVID-19 prevention and respiratory symptom treatment during the pandemic in Cusco, Peru: A cross-sectional survey. *PloS one*, 16(9), e0257165.
- 4- Remali, J., &Aizat, W. M. (2021). A review on plant bioactive compounds and their modes of action against coronavirus infection. *Frontiers in pharmacology*, 2256.
- 5- Abiyu, C., Endashaw, A., &Demelash, Z. (2021). Herbal medicine use for the management of COVID-19: A review article.
- 6-ul Qamar, M. T., Alqahtani, S. M., Alamri, M. A., & Chen, L. L. (2020). Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. *Journal of pharmaceutical analysis*, 7-Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., & Zhang, L. J. (2020). Coronavirus disease 2019 (COVID-19): a perspective from China. *Radiology*, 296 E15-E25
- 8-Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. *Coronaviruses*, 1-23.
- 9-Promptchara, E., Ketloy, C., &Palaga, T. (2020). Immune responses in COVID19 and potential vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pacific journal of allergy and immunology*,
- 10-Chen, Y., & Li, L. (2020). SARS-CoV-2: virus dynamics and host response. *The Lancet Infectious Diseases*,
11. Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., ... &Marasco, W. A. (2004). Potent neutralization of severe acute respiratory syndrome(SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proceedings of the National Academy of Sciences*, 101(8), 2536-2541.
12. Yu, X., Zhang, S., Jiang, L., Cui, Y., Li, D., Wang, D., ... & Wang, X. (2015). Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. *Scientific reports*, 5(1), 1-11.
13. Qiu, M., Shi, Y., Guo, Z., Chen, Z., He, R., Chen, R., ... & Yang, R. (2005). Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. *Microbes and infection*, 7(5-6), 882-889.

14. Modjarrad, K., Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K., Muthumani, K., ... & Maslow, J. N. (2019). Safety and immunogenicity of an antiMiddle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. *The Lancet Infectious Diseases*, 19(9), 1013-1022.
15. Emary, K. R., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., ... Oxford COVID-19 Vaccine Trial Group. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial. *The Lancet*, 397(10282), 1351-1362.
- 16-Rapaka, R. R., Hammershaimb, E. A., &Neuzil, K. M. (2022). Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. *Clinical Infectious Diseases*, 74(2), 352-358
- 17-Kasha, S., Gulbake, A., El-Amin III, S. F., & Gupta, A. (2021). COVID-19 vaccines: rapid development, implications, challenges and future prospects. *Human cell*, 34(3), 711-733.
- 18-Bok, K., Sitar, S., Graham, B. S., &Mascola, J. R. (2021). Accelerated COVID19 vaccine development: milestones, lessons, and prospects. *Immunity*, 54(8), 16361651.
- 19-Richman, D. D. (2021). COVID-19 vaccines: implementation, limitations and opportunities. *Global Health & Medicine*, 3(1), 1-5.
- 20-Brosh-Nissimov, T., Orenbuch-Harroch, E., Chowers, M., Elbaz, M., Neshet, L., Stein, M., ... & Wiener-Well, Y. (2021). BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clinical Microbiology and Infection*, 27(11), 1652-1657
- 21.Nayak, P., Kumar, T., Gupta, A. K., & Joshi, N. U. (2020). Peppermint a medicinal herb and treasure of health: A review. *J PharmacognPhytochem*, 9(3), 1519-1528.
- 22.Ahmadi, S., Rajabi, Z., &Vasfi-Marandi, M. (2018). Evaluation of the antiviral effects of aqueous extracts of red and yellow onions (*Allium Cepa*) against avian influenza virus subtype H9N2. *Iranian Journal of Veterinary Science and Technology*, 10(2), 23-27.
- 23.Dorsch, W., & Ring, J. (2021). Anti-inflammatory, anti-thrombotic and antiviral substances from Onions could be an option for the treatment of COVID-19: A hypothesis. *J. Bacteriol. Parasitol*, 12, 1000387.
- 24.Khubber, S., Hashemifesharaki, R., Mohammadi, M., &Gharibzahedi, S. M. T. (2020). Garlic (*Allium sativum* L.): a potential unique therapeutic food rich in organosulfur and flavonoid compounds to fight with COVID-19. *Nutrition Journal*, 19(1), 1-3.

- 25 .Donma, M. M., &Donma, O. (2020). The effects of allium sativum on immunity within the scope of COVID-19 infection. *Medical hypotheses*, 144, 109934.
26. Brasil, Sanitaria ANdV . Formu´ lario de Fitote´ rapicos da Farmacopeia Brasileira .´ Anvisa Brasılia; 2011.
- 27_ Galanakis, C. M., Aldawoud, T., Rizou, M., Rowan, N. J., & Ibrahim, S. A. (2020). Food ingredients and active compounds against the coronavirus disease (COVID-19) pandemic: A comprehensive review. *Foods*, 9(11), 1701
- 28_Paul, D. (2016). A review on biological activities of common Mallow (*Malvasylvestris* L.). *J. Life Sci*, 4, 1-5.ISO 690
- 29_Cutillo, F., D'Abrosca, B., DellaGreca, M., Fiorentino, A., &Zarrelli, A. (2006). Terpenoids and phenol derivatives from *Malvasilvestris*. *Phytochemistry*, 67(5), 481-485
- 30_Nosalova, G., Sutovska, M., Mokry, J., Kardosova, A., Capek, P., & Khan, M. T. H. (2005). Efficacy of herbal substances according to cough reflex. *Minerva Biotechnologica*, 17(3), 141.
- 31-Bassam A. Hassan, Fadil Mohsen Hamed , Maitham M. Abdulridha, FarqadM.Baqer 2022. Phytoconstituents Screened of Grapefruit Peels with Antimicrobial Properties of Naringin and Naringenin Extracted and Isolated from its. *Annals of the Romanian Society for Cell Biology*. 26, 01 (May 2022), 1160–1168.
- 32-Hussain, Maitham Y., Bassam A. Hassan, and Zaman K. Hanan. "Synthesis and Characterization of a new Schiff bases (3Z, 3Z)-3, 3'-((oxybis (4, 1-phenylene)) bis (azanylylidene)) bis (indolin-2-one)." *Turkish Journal of Computer and Mathematics Education (TURCOMAT)* 12.14 (2021): 3341-3351.
- 33-Hassan, Bassam A., Fadil Mohsen Hamed, and Farqad M. Baqer. "Green Chemistry. Review." *EFFLATOUNIA-Multidisciplinary Journal* 5.2 (2021).
- 34-Hamed, FADIL MOHSEN, BASSAM A. Hassan, and MAITHAM M. Abdulridha. "The antitumor activity of sulfonamides derivatives." *Int. J. Pharm. Res* 12 (2020): 2512-2519.
- Hassan, Bassam A., Hameedi N. Nasera, and Maitham M. Abdulridha. "Synthesis and antimicrobial evaluation of fused heterocyclic compound [1, 2, 4] triazolo [4, 3-b][1, 2, 4, 5] tetra zine." (2019).
- 35-Shalaal, Semma H., et al. "Maceration Techniques Extraction of *Thymus Vulgaris* and *Laurel (LaurusNobilis)* Leaves with Antibacterial Study." *Plant Archives* 19.2 (2019): 4041-4044.
- Hamed, Fadil M., et al. "Phytochemical and antimicrobial study of acetone extracts of menthe and olive leaves." *The Journal of Research on the Lepidoptera* 50.2 (2019): 51-6.
- 36-Abdulridha, Maitham M., et al. "Phytochemical and Antibacterial Activity of The *PegnumHarmala* Seeds and Its Alkaloids." *Plant Archives* 19.1 (2019): 1439-1444.

- 37-Hassan, Bassam A., Fadil Mohsen Hamed, and Firas F. Alyaseen. "Phytochemical screened, characterization and antibacterial activity of hesperetin and hesperidin extracted and isolated from dried oranges peels." (2018).
- 38-Abdulridha, Maitham M., Bassam A. Hassan, and Fadil M. Hamed. "Synthesis And Antibacterial Evaluation Of 1, 3, 4-Thiadiazole Containing 1, 3, 4-Oxadiazole Bearing Schiff Bases." *International Journal Of Pharmaceutical Research* (2018).
- 39-Alyaseen, Firas F., Bassam A. Hassan, and Haider S. Abdulhussein. "Extraction, Isolation And Chemical Identification of Piperine Alkaloid from Black Pepper Seeds And Its Antibacterial Activity." *Plant Archives* 18.2 (2018): 2171-2176.
- 40-Hasan, Bassam Abdul Hussein, et al. "Antimicrobial activity of ethanolic and aqueous extracts of pomegranate peel against Extended Spectrum Beta-Lactamase producing bacteria." *University of Thi-Qar Journal* 12.4 (2017): 1-14.
- 41-Alsafee, BassamAbdulhusseinHasan. "Synthesis, Identification and Antibacterial Activity of Some New Heterocyclic Compounds Contaning 1, 3, 4-Thiadiazole and 1, 3, 4-Oxadiazole Bearing Schiff Base." *Iraqi National Journal Of Chemistry* 17.2 (2017).
- 42-Alsafee, BassamAbdulhusseinHasan, and Maitham Mohamed Abdulridha. "Synthesis and characterization of Cu (II) and Fe (II) metal complexes of oxazepine derivative via Schiff base [Fe (HPOHBOT) Cl₂] and [Cu (HPOHBOT) Cl₂]." *African Journal of Pharmacy and Pharmacology* 10.35 (2016): 728-736.
- 43-Alsafee, BassamAbdulhusseinHasan. "Preparation and characterization of some transition metal complexes of 4-amino-N-(5-sulfanyl-1, 3, 4-thiadiazol-2-yl) benzenesulfonamide." *International Journal of Scientific & Engineering Research* 6.1 (2015): 37-45.
- 44--Alsafee, BassamAbdulhusseinHasan. "Preparation and characterisation of some transition metal complexes of new 4-[(5-ethyl-1, 3, 4-oxadiazol-2-yl) sulfanyl] aniline." *The Swedish Journal of Scientific Research* 1.6 (2014): 11-23.
- 45-Hasan, Bassam A., and Maitham M. Abdulridha. "Preparation and Characterisation of Sometransation Metal Complexes of New [Butanal (5-Ethyl-1, 3, 4-Oxadia-Zol-2-Yl) Hydrazone]." *The Swedish Journal of Scientific Research* 1.5 (2014): 23-36.
- 46-Hamed, Lecturer DrFadil Mohsen, AssisLectu, and Bassam A. Hassan. "The non-antibacterial activity of sulfonamide derivatives ناقتشمالير يتكبلة اذاضر يغلا تيلا عفلا ديمانو فلسلا."
- 47-Hassan, Bassam A., Farqad M. Baqer, and Maitham M. Abdulridha. "Design, Synthesis and Characterization of BenzoxazepineThiourea New Derivatives."
- 48-Jabir, Najim A. "RutaGraveolens (Hurb Of Grace)–Anti Bacterial Effects, A."